Literature DB >> 6592508

Evaluation of nystatin in prevention and elimination of oropharyngeal Candida in immunosuppressed patients.

A P Barrett.   

Abstract

Thirty-three patients with acute leukemia or lymphoma received an ongoing topical treatment with an oral suspension of nystatin during prolonged periods of intensive chemotherapy and severe granulocytopenia. The preparation proved ineffective in eliminating colonized Candida species from the oropharynx in ten of eleven patients at the time of admission and was of questionable value in preventing later colonization in others. The difficulties surrounding the identification of systemic candidiasis, its significance in the immunosuppressed patient, and the role of topical antifungal prophylaxis are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6592508     DOI: 10.1016/0030-4220(84)90128-2

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol        ISSN: 0030-4220


  5 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Oral symptoms and candida in the terminally ill.

Authors:  I G Finlay
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

3.  Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy.

Authors:  Joel B Epstein; Edmond L Truelove; Kimberly Hanson-Huggins; Lloyd A Mancl; Alice Chen; Oliver W Press; Stephen H Petersdorf; Thomas R Fritsche; Joshua D Epstein
Journal:  Support Care Cancer       Date:  2004-04-24       Impact factor: 3.603

4.  Problems in antifungal chemotherapy.

Authors:  D A Stevens
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

5.  Topical nystatin prophylaxis: a likely viable measure for reducing impact of candidemia in neurosurgical patients with early tracheostomy intubation.

Authors:  Giancarlo Ceccarelli; Simone Giuliano; Marco Falcone; Mario Venditti
Journal:  Crit Care       Date:  2013-02-18       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.